Filtered By:
Therapy: Gene Therapy

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 490 results found since Jan 2013.

Nanoscale polyelectrolyte complexes encapsulating mRNA and long-chained siRNA for combinatorial cancer gene therapy
Publication date: 25 August 2018Source: Journal of Industrial and Engineering Chemistry, Volume 64Author(s): Myung Goo Kim, Sung Duk Jo, Ji Hoon Jeong, Sun Hwa KimAbstractTo precisely regulate target genes that are abnormally expressed in cancers, we suggest an RNA-mediated multigene targeting system that co-encapsulates siRNA against vascular endothelial growth factor (VEGF) and mRNA encoding phosphatase and tensin homolog (PTEN). Polymerized long-chain siRNAs (L-siRNAs) formed stable and condensed nanocomplexes with mRNAs using thiolated glycol chitosans (tGCs) as gene carriers. The mRNA/L-siRNA/tGC nanocomplexes (MSNs) ...
Source: Journal of Industrial and Engineering Chemistry - July 11, 2018 Category: Chemistry Source Type: research

Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy.
Abstract Gene therapy has emerged as an alternative in the treatment of cancer, particularly in cases of resistance to chemo and radiotherapy. Different approaches to deliver genetic material to tumor tissues have been proposed, including the use of small non-coding RNAs due to their multiple mechanisms of action. However, such promise has shown limits in in vivo application related to RNA's biological instability and stimulation of immunity, urging the development of systems able to overcome those barriers. In this review, we discuss the use of RNA interference in cancer therapy with special attention to the role...
Source: Biomedical Microdevices - July 12, 2018 Category: Biomedical Engineering Authors: Costa DF, Torchilin VP Tags: Biomed Microdevices Source Type: research

----Delivery of siRNA therapeutics: PLGA nanoparticles approach.
Authors: Matta J, Maalouf R Abstract RNA interference is currently one of the most advanced genomic tools providing promising insight to manage countless pathophysiological conditions that seemed unapproachable few years ago. Researchers across the globe have devised numerous methods in which small RNA molecules can be administered into target cells to manipulate cellular functions at the molecular level and eradicate defects that lead to pronounced phenotypes, which might sometimes be as fatal as malignant tumors. The present review provides an overview of the non-viral delivery approaches for siRNA therapeutics w...
Source: Frontiers in Bioscience - Scholar - March 9, 2019 Category: Biomedical Science Tags: Front Biosci (Schol Ed) Source Type: research

Peptidyl Virus-Like Nanovesicles as Reconfigurable "Trojan Horse" for Targeted siRNA Delivery and Synergistic Inhibition of Cancer Cells
Small. 2022 Nov 13:e2204959. doi: 10.1002/smll.202204959. Online ahead of print.ABSTRACTThe self-assembly of peptidyl virus-like nanovesicles (pVLNs) composed of highly ordered peptide bilayer membranes that encapsulate the small interfering RNA (siRNA) is reported. The targeting and enzyme-responsive sequences on the bilayer's surface allow the pVLNs to enter cancer cells with high efficiency and control the release of genetic drugs in response to the subcellular environment. By transforming its structure in response to the highly expressed enzyme matrix metalloproteinase 7 (MMP-7) in cancer cells, it helps the siRNA esca...
Source: Cancer Control - November 13, 2022 Category: Cancer & Oncology Authors: Zixuan Wang Dongzhao Hao Yuefei Wang Jinwu Zhao Jiaxing Zhang Xi Rong Jiaojiao Zhang Jiwei Min Wei Qi Rongxin Su Mingxia He Source Type: research

Simultaneous Delivery of Doxorubicin and EZH2 ‐Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti‐Tumor Efficacy in Triple‐Negative Breast Cancer
A novel nanomedicine is synthesized based on Fe3O4 vortex nanorods loaded with doxorubicin (DOX) and EZH2 siRNAs and coated with a macrophage membrane. It shows a preferential tumor enrichment profile, thus leading to highly efficient drug delivery at the tumor site. Combining chemotherapy and gene therapy exhibits synergistic antitumor activity in a preclinical TNBC model. AbstractTriple-negative breast cancer (TNBC), one of the most aggressive types of breast cancer, currently lacks a targeted therapy and has a high clinical recurrence rate. The present study reports an engineered magnetic nanodrug based on Fe3O4 vortex ...
Source: Small - June 28, 2023 Category: Nanotechnology Authors: Yunshu Lu, Fenfen Gu, Yuwei Ma, Ruonan Li, Yi Luo, Xianhong Da, Lan Jiang, Xiang Li, Yan Liu Tags: Research Article Source Type: research

Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells
Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells Cancer Gene Therapy advance online publication, June 21 2013. doi:10.1038/cgt.2013.31 Authors: M Koldehoff, J L Zakrzewski, D W Beelen & A H Elmaagacli
Source: Cancer Gene Therapy - June 21, 2013 Category: Cancer & Oncology Authors: M KoldehoffJ L ZakrzewskiD W BeelenA H Elmaagacli Tags: advanced leukemia BCR–ABL GFI1B K562 small interfering RNA Source Type: research

Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA
Highlights: Abstract: Prostate cancer urgently needs an efficient therapy. Here we demonstrated that cisplatin combined with gene therapy by transfecting the attenuated Salmonella that carry a plasmid containing p53 gene and MDM2 siRNA provided a super-synergistic effect on the inhibition of prostate cancer growth in vivo. This synergistic therapy was associated with the induction of apoptotic cell death with a decreased Bcl2 to Bax expression ratio and increased expression of cleaved caspase 3 and caspase 9 in the prostate cancer xenograft. These results indicate that cisplatin-chemotherapy in combination with targeting t...
Source: Cancer Letters - June 21, 2013 Category: Cancer & Oncology Authors: Tao Jiang, Changdong Zhou, Junlian Gu, Yanan Liu, Lijing Zhao, Wei Li, Guanjun Wang, Yang Li, Lu Cai Tags: Research Articles Source Type: research

Efficient siRNA transfection to the inner ear through the intact round window by a novel proteidic delivery technology in the chinchilla
n, M Jia & Y Guo
Source: Gene Therapy - October 10, 2013 Category: Genetics & Stem Cells Authors: W QiD DingH ZhuD LuY WangJ DingW YanM JiaY Guo Tags: TAT double-stranded RNA-binding domains small-interfering RNA transfection inner ear chinchilla Source Type: research

Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo
Highlights: Abstract: SKOV3/DDP cells urgently require an efficient therapy to improve drug resistance. Here we show a critical role for cisplatin combined with gene therapy, using transfection of a p53 gene/MDM2-siRNA plasmid, in improving cisplatin sensitivity of SKOV3/DDP cells with a strong inhibition of tumor cell growth in vitro and in vivo. The effects may be associated with enhancement of intracellular platinum accumulation via decreased MDR1/P-gp and improvement of apoptotic resistance via increased P53, PUMA and NOXA expression. The combined therapy may efficiently inhibit cell invasion and migration via deceased...
Source: Cancer Letters - December 2, 2013 Category: Cancer & Oncology Authors: Junlian Gu, Yufeng Tang, Yanan Liu, Hua Guo, Yue Wang, Lu Cai, Yang Li, Bo Wang Tags: Research Articles Source Type: research

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells
maagacli
Source: Cancer Gene Therapy - June 6, 2014 Category: Cancer & Oncology Authors: M KoldehoffD W BeelenA H Elmaagacli Source Type: research

Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors
p; V P Torchilin
Source: Gene Therapy - October 30, 2014 Category: Genetics & Stem Cells Authors: S EssexG NavarroP SabhachandaniA ChordiaM TrivediS MovassaghianV P Torchilin Source Type: research

TGF-β1-siRNA delivery with nanoparticles inhibits peritoneal fibrosis
TGF-β1-siRNA delivery with nanoparticles inhibits peritoneal fibrosis Gene Therapy advance online publication, January 8 2015. doi:10.1038/gt.2014.116 Authors: H Yoshizawa, Y Morishita, M Watanabe, K Ishibashi, S Muto, E Kusano & D Nagata
Source: Gene Therapy - January 8, 2015 Category: Genetics & Stem Cells Authors: H YoshizawaY MorishitaM WatanabeK IshibashiS MutoE KusanoD Nagata Source Type: research

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research